(19)
(11) EP 2 315 780 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.09.2015 Bulletin 2015/39

(45) Mention of the grant of the patent:
19.08.2015 Bulletin 2015/34

(21) Application number: 09797499.2

(22) Date of filing: 15.07.2009
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 37/06(2006.01)
 A61K 39/395(2006.01)
A61P 19/02(2006.01)
(86) International application number:
PCT/EP2009/059030
(87) International publication number:
WO 2010/007082 (21.01.2010 Gazette 2010/03)

(54)

COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG FÜR THERAPEUTISCHE ANTIKÖRPER

COMPOSITIONS ET PROCÉDÉS À UTILISER POUR DES ANTICORPS THÉRAPEUTIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated Extension States:
AL BA RS

(30) Priority: 17.07.2008 EP 08160671
15.05.2009 EP 09160326

(43) Date of publication of application:
04.05.2011 Bulletin 2011/18

(73) Proprietor: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • HEUSSER, Christoph
    4002 Basel (CH)
  • NEUGEBAUER, Julia
    81677 München (DE)
  • SCHAADT, Eveline
    81543 München (DE)
  • URLINGER, Stefanie
    80689 München (DE)
  • WOISETSCHLAEGER, Maximilian
    2380 Perchtoldsdorf (AT)


(56) References cited: : 
WO-A-2006/073941
 WO-A-2008/008482
   
  • LEE CHINGWEI V ET AL: "Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells." BLOOD 1 NOV 2006, vol. 108, no. 9, 1 November 2006 (2006-11-01), pages 3103-3111, XP002509032 ISSN: 0006-4971
  • LIN WEI YU ET AL: "Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade." BLOOD 1 DEC 2007, vol. 110, no. 12, 1 December 2007 (2007-12-01), pages 3959-3967, XP002509033 ISSN: 0006-4971
  • EISENBERG R: "Combination biologics: 1 Stone, 2 birds" BLOOD 20071201 US, vol. 110, no. 12, 1 December 2007 (2007-12-01), page 3817, XP002509034
  • NG LAI GUAN ET AL: "B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUL 2004, vol. 173, no. 2, 15 July 2004 (2004-07-15) , pages 807-817, XP002509036 ISSN: 0022-1767
  • ZHANG XIN ET AL: "BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors." INTERNATIONAL IMMUNOLOGY JUN 2005, vol. 17, no. 6, June 2005 (2005-06), pages 779-788, XP002509035 ISSN: 0953-8178
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).